Skip to content
DraconiticResearch
Search Sources API
201,818 studies31 sourcesUpdated 4 min ago
Peer-reviewedCC BYJournal for ImmunoTherapy of Cancer

531 Phase I study to assess the safety, immunogenicity, and preliminary antitumor activity of the EBV mRNA vaccine (WGc-043 injection) in patients with R/R lymphoma

  • He Li1
  • Keshu Zhou2
  • Yuquan Wei3
  • Yuting Chen4
  • QingQing Cai5
  • Xudong Zhang6
  • Ting Niu7
  • Weili Zhao8
  • Shu Cheng9
  • Jia Miao1
  • Xiangrong Song10
10 affiliations
  1. 1Department of Hematology, Institute of Hematology, State Key Laboratory of Biotherapy, Collaborative Innovation Center of Bio2therapy, National Facility for Translational Medicine (Sichuan), West China Hospital, Sichuan University, Chengdu, Sichuan, China
  2. 22 Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China
  3. 3Laboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, No. 17, Block 3, Southern Renmin Road, Chengdu, Sichuan, China
  4. 41Department of Environmental and Occupational Health, Dongguan Key Laboratory of Environmental Medicine, School of Public Health, Guangdong Medical University, Dongguan, People`s Republic of China
  5. 512 Department of Pharmacy, Zhongshan Hospital, Fudan University, Shanghai, China
  6. 61 Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
  7. 72 Department of Hematology, West China Hospital of Sichuan University, Chengdu, Sichuan, China
  8. 8Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
  9. 9Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
  10. 10Center for High Altitude Medicine, State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy, National Facility for Translational Medicine (Sichuan), West China Hospital, Sichuan University, Chengdu, Sichuan, China
Open at sourcePDFDOICite

Related

  1. Analytical Characterization, Pharmacokinetics, Safety, and Preliminary Immunogenicity of GNR-062, an Agalsidase Beta Biosimilar Candidate, in Healthy Male Volunteers.
    Ivan Lyagoskin, Maksim Smolov, Oksana Markova +6
    Biotech (Basel (Switzerland))Peer-reviewedCC BYFull textPhysiologyEurope PMC
  2. Antitumor Activity of a Bupleurum chinense-Derived Vesicle-like Particle Preparation in MOC1 Oral Squamous Cell Carcinoma Models
    BiomedicinesPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  3. Lipid-based mRNA chimeric antigen receptor T cells for enhanced in vitro antitumor activity
    Haixia Gao, Yuan Fang, Zhidan Tian +6
    iSciencePeer-reviewedCC BY-NC-ND 4.0Full textOncologyCrossrefEurope PMC
  4. CRISPRa screen unveils noncanonical NF-κB to boost the antitumor activity of TCR-based CAR-T cells
    Hanyang Yu, Yingxin Wu, Yue Liu +5
    Cellular and Molecular ImmunologyPeer-reviewedLicence not statedFull textOncologyPMC
  5. 318 CAR-T and CAR-NK cell combination therapy targeting DLL3 or CD70 surface antigens promotes synergistic antitumor activity in small cell lung cancer
    Rizwan Romee, David Barbie, Eden Bobilev +5
    Journal for ImmunoTherapy of CancerPeer-reviewedCC BYOncologyDOAJ

Cite

BibTeXRIS
BibTeX
@article{li2026phase,
  title = {{531 Phase I study to assess the safety, immunogenicity, and preliminary antitumor activity of the EBV mRNA vaccine (WGc-043 injection) in patients with R/R lymphoma}},
  author = {He Li and Keshu Zhou and Yuquan Wei and Yuting Chen and QingQing Cai and Xudong Zhang and Ting Niu and Weili Zhao and Shu Cheng and Jia Miao and Xiangrong Song},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2026},
  month = nov,
  doi = {10.1136/jitc-2026-sitc2026.0531},
  url = {https://doi.org/10.1136/jitc-2026-sitc2026.0531},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - 531 Phase I study to assess the safety, immunogenicity, and preliminary antitumor activity of the EBV mRNA vaccine (WGc-043 injection) in patients with R/R lymphoma
AU  - He Li
AU  - Keshu Zhou
AU  - Yuquan Wei
AU  - Yuting Chen
AU  - QingQing Cai
AU  - Xudong Zhang
AU  - Ting Niu
AU  - Weili Zhao
AU  - Shu Cheng
AU  - Jia Miao
AU  - Xiangrong Song
PY  - 2026
DA  - 2026/11/08
JO  - Journal for ImmunoTherapy of Cancer
DO  - 10.1136/jitc-2026-sitc2026.0531
UR  - https://doi.org/10.1136/jitc-2026-sitc2026.0531
SN  - 2051-1426
ER  -